An aza-BODIPY-based NIR-II luminogen enables efficient phototheranostics

Abstract

The fabrication of high-performance second near-infrared (NIR-II) biological window fluorophore is in urgent need for precise diagnosis and treatment of cancer. Nevertheless, the construction of phototherapeutic agents in the NIR-II...

Comparison of the In Vitro and In Vivo Behavior of a Series of NIR-II-Emitting Aza-BODIPYs Containing Different Water-Solubilizing Groups and Their Trastuzumab Antibody Conjugates

“…We have also recently used this approach for aza-BODIPYs emitting in the NIR-II (named SWIR-Wazaby), compounds presenting no cytotoxicity. , Indeed, working in the NIR-II region–i.e., between 1000 and 1700 nm–enables a greatly increased resolution compared to the NIR-I region, and thus to obtain better quality images. − …”

A diketopyrrolopyrrole-based small molecule with an extended conjugated skeleton and J-aggregation behavior for 808 nm laser triggered phototheranostics

“…These benefits are due to the inert behavior of biological tissues towards light in this region. 2 Photothermal therapy (PTT), a process in which a photothermal agent eradicates tumor cells by converting light energy into hyperthermia, 3 offers regional selectivity, non-invasive treatment, and fewer side-effects compared to traditional treatments such as chemotherapy, radiotherapy and surgical operation. 4 In the last decade, phototheranostic agents that integrate NIR-II FI and PTT have been developed.…”

NIR‐II Imaging‐Guided Mitochondrial‐Targeting Organic Nanoparticles for Multimodal Synergistic Tumor Therapy

“…Until now, fluorescence imaging (FI) with high sensitivity has been extensively explored for real-time phototherapy of tumors. [15,16] FI in the second near-infrared window (NIR-II, 1000-1700 nm) shows the advantages of higher spatial resolution and deeper tissue penetration compared to the first near-infrared region (NIR-I, 650-900 nm), which provides a promising way for outstanding phototheranostics. [16] However, current "always-on" NIR-II phototheranostic fluorophores fundamentally result in false positives, low tumor-to-normal tissue contrast, and unsatisfied NIR-II imaging for tumor therapy.…”

“…[15,16] FI in the second near-infrared window (NIR-II, 1000-1700 nm) shows the advantages of higher spatial resolution and deeper tissue penetration compared to the first near-infrared region (NIR-I, 650-900 nm), which provides a promising way for outstanding phototheranostics. [16] However, current "always-on" NIR-II phototheranostic fluorophores fundamentally result in false positives, low tumor-to-normal tissue contrast, and unsatisfied NIR-II imaging for tumor therapy. Therefore, many efforts have been committed to developing stimuli-responsive NIR-II fluorophore by responding to the tumor microenvironment (TME) or the cellular signals, including redox, pH, enzyme, etc.…”

“…Therefore, many efforts have been committed to developing stimuli-responsive NIR-II fluorophore by responding to the tumor microenvironment (TME) or the cellular signals, including redox, pH, enzyme, etc. [16,17,18] Despite much progress that has been achieved in recent years, NIR-II imaging-guided tumor therapy with excellent tumor-specificity and satisfying antitumor effects remains a significant challenge.…”